Table 1. Patient Characteristics.

From: Exploring Predictive Risk Factors of Infusion Reactions with First Pertuzumab Administration in HER2-positive Breast Cancer Patients: A Single Institution Experience

Number of patients 57 (100%)
Gender, n female 56 (98%)
male 1 (2%)
Age, years 60.0 (28-84)
Height, m 1.56 (1.45-1.70)
Body weight, kg 53.9 (40.3-100)
BMI, kg/m2 21.8 (17.2-40.2)
Histories, n allergy 26 (46%)
smoking 19 (33%)
alcohol consumption 24 (42%)
Treatment settings, n pre-operative 20 (35%)
post-operative 10 (18%)
recurrent 15 (26%)
stage IV 12 (21%)
Drugs combined with Pmab-Tmab, n docetaxel 39 (68%)
paclitaxel 5 (9%)
capecitabine 1 (2%)
exemestane 1 (2%)
none 11 (19%)
Previous history of chemotherapy, n
any time 45 (79%)
within 3 months Total 38 (67%)
 anthracycline + cyclophosphamide 30 (53%)
 paclitaxel 1 (2%)
 Tmab 4 (7%)
 Tmab + paclitaxel 1 (2%)
 lapatinib + capecitabine 1 (2%)
 capecitabine 1 (2%)
 
 none 12 (21%)
Estrogen receptor, n positive 36 (63%)
negative 21 (37%)
IR occurrence, n yes 25 (44%)
no 32 (56%)
Table 2. Univariate Analysis of Demographic and Clinical Variables between Patients with and without Infusion Reaction (IR).

From: Exploring Predictive Risk Factors of Infusion Reactions with First Pertuzumab Administration in HER2-positive Breast Cancer Patients: A Single Institution Experience

Without IR
(n = 32)
With IR
(n = 25)
P-value
Patient characteristics
 Age, years 52 (28-84) 64 (33-83) 0.16
 Height, m 1.56 (1.45-1.68) 1.56 (1.46-1.70) 0.91
 Body weight, kg 55 (41-97) 50 (40-100) 0.092
 BMI, kg/m2 22.4 (17-37) 20.3 (17-40) 0.058
 History of allergy, n 16 (50%) 10 (40%) 0.59
 History of smoking, n 8 (25%) 11 (44%) 0.30
 History of alcohol consumption, n 15 (47%) 9 (36%) 0.43
Estrogen receptor, n
 positive 20 (63%) 16 (64%) 1.0
 negative 12 (38%) 9 (36%)
Treatment settings, n
 pre-operative 11 (34%) 9 (36%) 0.031*
 post-operative 2 (6%) 8 (32%)
 recurrent 12 (38%) 3 (12%)
 stage IV 7 (22%) 5 (20%)
Anti-cancer drug administration within 3 months before Pmab, n
 anthracycine 13 (41%) 17 (68%) 0.061
 none or other than anthracycline 19 (59%) 8 (32%)
Blood test data
 WBC, /μL 5200 (2600-15300) 5000 (1700-15700) 0.57
 NTR, /μL 3400 (1600-12900) 3500 (850-13500) 0.63
 LYM, /μL 870 (370-2290) 860 (200-2340) 0.48
 MON, /μL 300 (160-980) 320 (100-1600) 0.76
 RBC, 104/μL 400 (300-500) 350 (210-480) <0.001
 Hb, g/dL 12.0 (9.6-14) 10.8 (6.5-14) 0.0011
 Hct, % 36 (30-44) 32 (19-42) <0.001
 MCV, fL 93 (81-100) 93 (79-99) 0.61
 MCH, pg 31 (24-42) 31 (26-35) 0.49
 MCHC, % 33 (30-35) 34 (32-35) 0.21
 PLT, 104/μL 27 (9.5-52) 26 (4.6-55) 0.69
 NLR 3.9 (1.1-14) 4.0 (1.3-26) 0.86
 MLR 0.36 (0.14-1.3) 0.49 (0.11-1.3) 0.37
 PLR 300 (110-1110) 300 (140-1000) 0.88
 AST, U/L 21 (10-53) 21 (11-420) 0.74
 ALT, U/L 17 (5-77) 16 (8-91) 0.64
 ALP, U/L 230 (60-650) 240 (95-2900) 0.50
 γ-GTP, U/L 28 (18-150) 22 (15-1400) 0.17
 LDH, U/L 220 (160-380) 210 (140-1400) 1.0
 TP, g/dL 6.9 (6.3-7.5) 6.8 (5.8-7.9) 0.27
 Alb, g/dL 4.1 (2.9-4.7) 3.9 (2.4-4.5) 0.11
 BUN, mg/dL 12 (7.0-55) 13 (6.1-21) 0.55
 Cre, mg/dL 0.59 (0.40-1.80) 0.56 (0.41-0.81) 0.81
 CRP, mg/dL 0.090 (0-3.9) 0.070 (0-5.2) 0.52
Table 3. Univariate Logistic Regression Analysis Focusing on Hemoglobin Values.

From: Exploring Predictive Risk Factors of Infusion Reactions with First Pertuzumab Administration in HER2-positive Breast Cancer Patients: A Single Institution Experience

Variables Odds ratio Log odds ratio 95% CI
Hb (P) 0.22 −1.53 [0.044, 0.58]
Hb (P) - Hb (A) 0.29 −1.25 [0.092, 0.61]
Hb (P)/HB (A) 3.5 × 10−8 −17.2 [5.0 × 10−15, 1.1 × 10−3]
PAGE TOP